Physician profile
Ramkumar Jayagopalan
NPI 1861426181
$1,389.40
in general payments reported to CMS, 2019-2025
21 companies · $240 in 2025
The $240 reported for 2025 was more than what 79% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $142 · 2021: $235 · 2022: $102 · 2023: $131 · 2024: $427 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $798.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $297.48 | 2021-2025 | Qelbree, Qelbree |
| Pfizer INC. | $223.13 | 2019-2025 | |
| Cranial Technologies, INC | $133.20 | 2021-2024 | Doc Band |
| Alk-Abello, INC | $89.43 | 2024-2025 | Odactra, Grastek, Ragwitek |
| Sanofi Pasteur INC. | $83.49 | 2021-2024 | |
| Tris Pharma INC | $61.29 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.56 | 2020-2021 | |
| Seqirus USA INC | $52.93 | 2022-2025 | Flucelvax Quadrivalent, Fluad, Flucelvax |
| Ironshore Pharmaceuticals INC. | $50.49 | 2019-2020 | |
| Corium, LLC | $46.36 | 2021-2023 | Azstarys |
| Aytu Biopharma, INC. | $45.52 | 2025 | |
| Merck Sharp & Dohme LLC | $42.65 | 2020-2025 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Astrazeneca Pharmaceuticals Lp | $36.85 | 2023-2024 | Flumist Quadrivalent |
| Rhythm Pharmaceuticals, INC. | $32.42 | 2022 | |
| Adlon Therapeutics L.P. | $32.37 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $23.62 | 2023 | Immunocap |
| Verrica Pharmaceuticals INC. | $19.25 | 2024 | Ycanth |
| Biomarin Pharmaceutical INC. | $17.51 | 2023 | Voxzogo 1.2mg |
| Collegium Pharmaceutical, INC. | $16.03 | 2025 | Jornay Pm |
| Glaxosmithkline, LLC. | $14.17 | 2023 | Bexsero |
| Vertical Pharmaceuticals, LLC | $13.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramkumar Jayagopalan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.